NCT07266012Completed
Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
This prospective observational study aims to evaluate the relationship between the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk assessment model in adult patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH). The study investigates whether VEXUS can enhance risk stratification and predict haemodynamic congestion by correlating VEXUS with functional, biochemical, and invasive haemodynamic parameters.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 86 (actual)
- First submitted
- 23 Nov 2025
- Start date
- 7 May 2025
- Primary completion date
- 5 Nov 2025
- Lead sponsor
- Istanbul University - Cerrahpasa
- NCT number
- NCT07266012
What you commit to
- Study type: Observational
- Participants enrolled: 86
- From 7 May 2025 to the primary completion date, 5 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pulmonary hypertension other than WHO Group 1, including:
- PH due to left heart disease (WHO Group 2)
- PH due to chronic lung disease or hypoxaemia (WHO Group 3)
- Chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4)
- Multifactorial PH (WHO Group 5)
- Eisenmenger syndrome
- Complex or unrepaired congenital heart disease
- Suspected pulmonary veno-occlusive disease (PVOD)
- Acute decompensated right heart failure
- Severe hepatic impairment (Child-Pugh Class C)
- Active infection
Lab values
- Severe renal dysfunction (eGFR \<30 mL/min/1.73 m²)
Other
- Pulmonary capillary haemangiomatosis (PCH)
- Congestive hepatopathy
- Pregnancy
- Inability or unwillingness to provide informed consent
- Poor ultrasonographic acoustic window preventing adequate VExUS scoring
Who the study is looking for
- Adults aged ≥18 years
- Established diagnosis of WHO Group 1 pulmonary arterial hypertension (PAH)
- Stable outpatient clinical status at the time of VExUS ultrasonography
- Venous Excess Ultrasound Score (VExUS) evaluation performed with adequate ultrasonographic acoustic windows
- Clinically indicated right heart catheterisation (RHC) performed within ±60 days of VExUS assessment
- Availability of ESC/ERS 2022 simplified risk assessment variables (WHO functional class, BNP/NT-proBNP, and 6-minute walk distance)
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University Cerrahpaşa Institute of Cardiology Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.